Cinitaprid expands treatment options for functional dyspepsia

Czech version

Authors: Jiří Slíva
Authors‘ workplace: Ústav farmakologie 3. LF UK, Praha
Published in: Gastroent Hepatol 2024; 78(5): 441-443
Category: Drug Profile
doi: https://doi.org/10.48095/ccgh2024441

Overview

Treatment of functional dyspepsia is often medically difficult and requires a comprehensive approach, including the drug group prokinetics. In the Czech Republic, it is now being expanded to include the active substance cinitapride. The presented text summarizes its basic pharmacological properties and summarizes the available relevant aspects of its clinical use.

Keywords:

functional dyspepsia – prokinetics – cinitapride

Sources

1. Monés J, Espinós JC, Carrió I et al. Gastric emptying in reflux esophagitis. Effect of metoclopramide and cinitapride. Med Clin (Barc) 1989; 93 (9): 331–334.

2. Yamamoto FJK, López MA, Chávez MCI et al. Eficacia y tolerabilidad de la cinitaprida en pacientes con reflujo gastroesofágico, dispepsia funcional y síndrome de intestino irritable. Med Int Mex 2005; 21 (1): 3–10.

3. Portincasa P, Mearin F, Robert M et al. Efficacy and tolerability of cinitapride in the treatment of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol 2009; 32 (10): 669–676. doi: 10.1016/j.gastrohep.2009. 06.013.

4. Baqai MT, Malik MN, Ziauddin F. Efficacy and safety of cinitapride in functional dyspepsia. J Pak Med Assoc 2013; 63 (6): 747–751.

5. Qi Q, Wang N, Liu H et al. Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis. BMC Gastroenterol 2023; 23 (1): 370. doi: 10.1186/s12876-023-03014-9.

6. Du Y, Su T, Song X et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol 2014; 48 (4): 328–335. doi: 10.1097/MCG.000000000 0000033.

7. Gallego Santos J, Fombuena Filpo J, Martínez López J. Efficacy and tolerance of cinitapride on the disturbances of gastrointestinal transit. Rev Med Univ Navarra 1991; 36 (3): 12–18.

8. Surós A, Adell F, De Novoa V et al. Cinitapride on the treatment of gastroesophageal reflux. Comparative study with metoclopramide and placebo. Rev Med Univ Navarra 1992; 37 (1): 18–23.

9. Mora F, Añón R, Liceras V et al. Metoclopramide versus cinitapride in the treatment of functional dyspepsia. An Med Interna 1993; 10 (7): 323–326.

10. Rani PS, Devi V, Sonia S. Comparative study of the efficacy and tolerance of prokinetic drugs –⁠ metoclopramide and cinitapride in the treatment of functional dyspepsia –⁠ a randomized controlled trial. Int J Res Pharmacol Pharmacother 2013; 2 (1): 307–331.

11. Valdovinos MA, Teutle RAM, Sepulveda J et al. Efecto de levosulpirida versus cinitaprida en el control de los síntomas, la calidad de vida y el vaciamiento gástrico en pacientes con gastroparesia diabética. Estudio piloto aleatorizado, doble ciego y a 6 meses de tratamiento. Acta Gastroenterol Latinoam 2017; 47 (4): 277–287.

12. Zhang X, Wang Y, Cheng J et al. Pharmacokinetics and tolerability of cinitapride in healthy Chinese volunteers: a randomized, open-label, single -⁠ and multiple-dose study. Xenobiotica 2019; 49 (3): 313–321. doi: 10.1080/00498254.2018.1447710.

13. Campodónico DM, Zubiaur P, Soria-Chacartegui P et al. CYP2C8*3 and *4 define CYP2C8 phenotype: an approach with the substrate cinitapride. Clin Transl Sci 2022; 15 (11): 2613–2624. doi: 10.1111/cts.13386.

14. Robert M, Salvà M, Segarra R et al. The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos 2007; 35 (7): 1149–1156. doi: 10.1124/dmd.106.010835.

doc. MUDr. Jiří Slíva, Ph.D.

Ústav farmakologie 3. LF UK

Ruská 87

100 00 Praha 10

jiri.sliva@lf3.cuni.cz